Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is to provide a public service. To alert people to a scam.
I agree with Sid. Just consider all the spin off companies. This is a ponzi scheme.
The point is, it is not an unbiased article, as it is often implied to be when it is cited in posts. The amount for compensation doesn't really matter...LOL
Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc.
Bend over and wait for the large deposit is more like it.
I don't know what stock you are referring to. The last financial report for ENTB was June 22.
Why can't it just be timely like most other legitimate companies? OTC rules state that quarterly reports get 45 days. Annual reports get 90 days.
Quarterly report is 45 days late. Is ENTB going dark like BMSN did?
The 10-Q is what should be forthcoming. It's over a month late.
The timely reporting of financials is always a good indication of how well a company is managed.
BMSN closing in on its eleventh anniversary. What have they accomplished in that time?
Read the disclaimer at the bottom of the article. It's a promo piece paid for by RGBP. Not a real article.
Small Cap Solutions...LOL
I know that this is supposed to get everybody excited that NR2F6 is going to get the same deal but they have basically just put out a PR for a competitor that got there first. Kind of a strange thing to do. I guess Koos didn't have any good news of his own.
Wouldn't it be nice if Koos was more open about it. An announcement and explanation about the nature and purpose of all of these subs would do a lot for shareholder confidence. Instead everything appears to be underhanded. I can't think of another small biotech that has created so many subsidiaries.
Maybe Checkpoint Immunology is now called KCL? There should have been an 8-k if they changed the name or created a new spin off. There was an 8-k filed announcing Checkpoint.
I wonder who is purchasing all all of the convertible notes? If it is a single entity then they getting close to being the majority owner.
What is KCL Therapuetics, inc ? And what is it's interest in NR2F6 ? Why has there been no mention of KCL Therapeutics , Inc before? Any guesses as to what KCL stands for? The answer is pretty obvious.
Per the latest 10-q there is now $3,258,974 in derivative liability. This amounts to 206,000,000 additional shares at %75 of the current share price. This is the possible dilution that is hanging over this stock due to financing this company with convertible notes. Is it any wonder that the share price is going down.
It was made obsolete by small molecules.
Yes we keep getting reminded of that with every PR. It appears that the compound is even more effective at removing money from investors portfolios.
It is dilution in a big way. But by kicking the can down the road with convertible notes unsuspecting investors that don't read the financials don't see the massive dilution that is coming down the pike. I don't see any of the happy-go-luckys addressing my comments but that's probably because the muted me. The sun always shines on your ads when you bury your head in the sand.
They only paid .015 for them. %30 return in one year would sound good to me.
There are more. If I recall they have a longer maturity. I'm sure that there will be additional convertible notes on the next 10-Q. Read through the last 10-Q and you will see. It's how they're raising funds now, every month.
At one time it was short sellers. Then for a long time it was MMs manipulating the price. Now it's a shakeout. Whatever, it's all just excuses for this being a really bad investment. Nobody with the funds to actually lift the share price is interested in it.
It's kind of like the DMV keeps a list of people that are likely to drive a vehicle.
Should read "in vivo". Not in vitro
If they are going the vetrinary route then they have to file and get approved for a NADA be for they do any in vitro testing.
The point is that Koos is now only focused on Zander.
Once again this company is changing course. Now it's dogs and cats with Sander. A subsidiary of a subsidiary of a subsidiary. Is this really what you thought you were investing in when you bought this stock? Or are you just Ok with it because it still sounds good?
It's like convertible notes are like McDonalds gift certificates around here. Actually they are incredibly dilutive if they are not paid off before maturity.
Does anyone investing in this bother reading the quarterly reports? The first eight convertible notes come due on 8/26/17, 9/8/17, 9/20/17, 10/7/17,10/31/17, 10/31/17, 10/31/17, and 10/31/17. The conversion price is at .0125 per share so the note holder could triple their money at the current share price. That is not nothing. Of course if they do try to sell too quickly they will overwhelm the market and drive the price down quickly. Do not think that there is no dilution going on. There is every month now in the form of these notes.
Once again let me point out, wait until those convertible notes mature. Unless they were sold to some grandmother in a coma I would expect the holder of them to cash out as soon as possible. Based on current volume I don't think it would take much more that a month or two worth of them being sold to sink both common and preferred stocks to sub penny.
Someone told me I should check back in 2 months to see how much progress has been made. Well still not much happening and certainly no deal has been announced.
I don't know. There is no conversion date mentioned. At least with the RGBP convertible notes we have a maturity date. Unless I missed something for all we know these convertible shares could be redeemed for common shares and sold off at any time. It's all very disconcerting because they are borrowing a lot of cash every month at what amounts to well over a 100% interest rate. These convertible shares issued in just the last few months have the potential to triple the outstanding share count.
They don't have to be tradable. They are convertible to common shares. Do a little research on the entities that bought these preferred shares and you will find that they are the same long time cronies of Koos that have been sucking money out of these companies for years by buying shares for pennies on the dollar in backroom deals.
Faith or greed?
Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of (i) $0.01 per share or (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.
Completely different molecules than NR2F6.
I suppose he means preclinical testing which is the next step. That will take a couple of years and will also cost millions to complete. Then they can apply for FDA approval. Maybe they can keep getting the convertible notes to pay for it. Unfortunately there will soon be billions of shares of RGBP. Just like BMSN.